Bedrijfsvoering Eli Lilly and Company

LLY

US5324571083

Farmaceutische producten

Geschatte realtime Cboe BZX Andere beurzen 17:41:37 24-06-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
769,68 ^USD	-0,12%		-2,75%	-0,32%

16:51	Novo Nordisk Lanceert Afslankmiddel Wegovy in India	MT
15:33	Novo Nordisk introduceert afslankmiddel Wegovy in India als concurrent voor Lilly's Mounjaro	RE

Uitvoerend comité: Eli Lilly and Company

Bedrijfsleider

Beklede functiesVan

David Ricks

57 jaar

Chief Executive Officer	01-01-2017
President	01-01-2017

Diogo Rau

50 jaar

Chief Tech/Sci/R&D Officer

17-05-2021

Eric Dozier

58 jaar

Human Resources Officer

31-08-2022

Ruth Gimeno

President

David Hyman

Chief Tech/Sci/R&D Officer

16-10-2023

Donald Zakrowski

Comptroller/Controller/Auditor

01-11-2012

Daniel Skovronsky

51 jaar

Chief Tech/Sci/R&D Officer

Lucas Montarce

48 jaar

Director of Finance/CFO

09-09-2024

Anat Hakim

55 jaar

General Counsel	03-02-2020
Corporate Secretary	-

Samenstelling van de raad van bestuur: Eli Lilly and Company

Directeur

RadenVan

David Ricks

57 jaar

Compensation Committee

12-04-2018

Ralph Alvarez

69 jaar

Audit Committee
Compensation Committee Chair
Compensation Committee
Governance Committee
Nominating Committee

Gabrielle Greene-Sulzberger

64 jaar

Audit Committee	25-01-2021
Governance Committee
Nominating Committee	01-12-2018

Mary Lynne Hedley

62 jaar

Governance Committee Chair	16-08-2019
Nominating Committee Chair	16-08-2019
Audit Committee	23-02-2021

Jamere Jackson

55 jaar

Governance Committee	01-10-2016
Audit Committee Chair	01-10-2016

Juan Luciano

63 jaar

Compensation Committee
Governance Committee Chair

Jon Moeller

61 jaar

Audit Committee	01-12-2024
Governance Committee	01-12-2024

William Kaelin

67 jaar

Governance Committee

Kimberly Johnson

52 jaar

Compensation Committee

16-02-2021

Jon Fyrwald

64 jaar

Compensation Committee

Katherine Baicker

53 jaar

Director/Board Member	12-12-2011
Independent Dir/Board Member	12-12-2011

Recente benoemingen: Eli Lilly and Company

Van insuline tot Ozempic, de geschiedenis van de CEO's van Novo Nordisk	16/05	RE
CEO van Novo Nordisk treedt af	16/05	RE
INSTANT VIEW-Wegovy-fabrikant Novo Nordisk ontslaat CEO nu concurrentie op markt voor obesitasmedicijnen toeneemt	16/05	RE
INSTANT VIEW - Verrassend vertrek van CEO Novo Nordisk na tegenslagen op de markt voor gewichtsverlies	16/05	RE
Procaps Group S.A. kondigt wijzigingen in de raad van bestuur aan, met ingang van 8 mei 2025	13/05	CI
Eli Lilly and Company, Lilly Cardiometabolic Health en Lilly Usa, Llc kondigen benoemingen van leidinggevenden aan	08/05	CI
Roche kondigt wijzigingen in het management aan	20/03	CI

Meer nieuws

Voormalige zaakvoerders en bestuurders: Eli Lilly and Company

Insider

Beklede functies

VanTot

Kathi P. Seifert

Director/Board Member	01-01-1995	03-05-2021
Independent Dir/Board Member	01-01-1995	03-05-2021

Ellen Marram

Director/Board Member	01-01-2002	01-05-2019
Chairman	09-05-2013	08-07-2013
Independent Dir/Board Member	01-01-2012	01-05-2019

John Lechleiter

Director/Board Member	01-01-2005	01-01-2009
Chief Executive Officer	01-04-2008	31-12-2016
Chairman	01-01-2009	31-05-2017
Chief Operating Officer	01-01-2005	01-04-2008
General Counsel	01-01-1994	01-01-1998
Corporate Officer/Principal	01-01-1998	01-01-2005
President	01-01-2005	31-12-2016

Derica Rice

Comptroller/Controller/Auditor	01-01-2003	01-01-2006
Director of Finance/CFO	01-01-2006	01-01-2017

Franklyn Prendergast

Director/Board Member	01-04-1995	01-01-2017
Independent Dir/Board Member	01-04-1995	01-01-2017

Karen Horn

Director/Board Member	01-01-1987	02-05-2016
Independent Dir/Board Member	15-04-2011	02-05-2016

Win Bischoff

Director/Board Member	01-04-2000	05-05-2014
Independent Dir/Board Member	25-04-2011	05-05-2014

Robert A. Armitage

Director/Board Member	26-04-2011	05-05-2011
General Counsel	01-11-1999	31-12-2012

Arnold Hanish

Comptroller/Controller/Auditor

01-01-1984

01-12-2012

Martin Feldstein

Director/Board Member	01-01-2002	04-06-2012
Independent Dir/Board Member	15-04-2011	04-06-2012

Frank M. Deane

Director/Board Member	05-05-2011	06-05-2011
Corporate Officer/Principal	01-01-1986	01-01-2012

Anne Nobles

Director/Board Member	05-05-2011	07-09-2011
General Counsel	01-01-1990	01-01-2012

Alex Michael Azar

Public Communications Contact	01-06-2007	01-04-2009
Corporate Officer/Principal	01-04-2009	01-12-2011

David Bredt

Corporate Officer/Principal

01-01-2004

01-01-2011

Gino Santini

Corporate Officer/Principal

01-01-1990

01-12-2010

Steven Paul

Chief Tech/Sci/R&D Officer

01-04-1993

01-02-2010

Anthony John Murphy

Human Resources Officer

01-01-1980

30-04-2009

J. Michael Cook

Director/Board Member

01-01-2005

20-04-2009

Deirdre Connelly

Human Resources Officer	01-01-2003	01-06-2005
Corporate Officer/Principal	01-06-2005	30-01-2009

Charles E. Golden

Director of Finance/CFO

01-03-1996

30-04-2006

John Edward Victor Rose

Director/Board Member

14-10-2005

Steven C. Beering

Director/Board Member

18-04-2005

Bryan Dunnivant

Chief Operating Officer

01-01-2001

31-12-2004

Vanessah Ng

Corporate Officer/Principal

31-12-2004

Webster Dunbar

Chief Tech/Sci/R&D Officer	01-01-1999	01-01-2003
Corporate Officer/Principal	01-01-2003	01-09-2004

Joseph Zakrzewski

Corporate Officer/Principal

01-01-2003

01-01-2004

Pedro Granadillo

Human Resources Officer	01-01-1970	01-01-2004
Corporate Officer/Principal	01-01-1970	01-01-2004

Scott Priebe

Corporate Officer/Principal

31-12-2003

Alan Breier

Chief Tech/Sci/R&D Officer

01-08-2003

August M. Watanabe

Corporate Officer/Principal

01-06-2003

Brett L. Schmidli

Corporate Officer/Principal

01-01-1992

01-01-2002

Jerome H. Fleisch

Corporate Officer/Principal

01-01-1974

31-12-2001

Stephen W. Kaldor

Corporate Officer/Principal

01-06-1989

31-12-2001

David A. Broecker

Corporate Officer/Principal

01-08-1985

01-01-2001

George Fisher

Director/Board Member

01-01-2000

John T. Boris

Corporate Officer/Principal

02-01-1988

01-01-1998

Lionel Carnot

Corporate Officer/Principal

01-01-1995

01-01-1997

Paul F. Banta

General Counsel

01-06-1987

01-01-1995

Alfred G. Gilman

Director/Board Member	01-01-1995	-
Independent Dir/Board Member	15-04-2011	-

James Cornelius

Director/Board Member	01-01-1983	01-01-1995
Director of Finance/CFO	01-01-1983	01-01-1995

Ron D. Henriksen

Corporate Officer/Principal

01-01-1971

01-01-1994

B. Jack Miller

Human Resources Officer

01-01-1968

31-12-1987

James F. White

Corporate Officer/Principal

Mike Peterson

Corporate Officer/Principal

Simon Li

Corporate Officer/Principal

Rafik H. Bishara

Corporate Officer/Principal

Michael Heffernan

Corporate Officer/Principal

Michael Sherman

Corporate Officer/Principal

Seth D. Goldblum

Corporate Officer/Principal

Erin Markey

Corporate Officer/Principal

Stephen Andrade

Corporate Officer/Principal

Molly Montgomery

Corporate Officer/Principal

Jack Steele

Corporate Officer/Principal

Eric E. Easom

Corporate Officer/Principal

Pat O'Day

Corporate Officer/Principal

Paul A. Hyslop

Corporate Officer/Principal

Dennis W. White

Corporate Officer/Principal

Stephen E. Butts

Corporate Officer/Principal

Ronald A. Matricaria

Corporate Officer/Principal

Robert W. McLaughlin

Corporate Officer/Principal

Wei Zhang

Corporate Officer/Principal

Todd F. Kirschner

Corporate Officer/Principal

Aaron Davidson

Corporate Officer/Principal

John R. Uhrin

Corporate Officer/Principal

Jim R. Baumgardt

Director/Board Member

James B. Lootens

Corporate Secretary

John Barnard

Corporate Officer/Principal

Donald C. Aroborgast

Corporate Officer/Principal

Anton G. Gueth

Corporate Officer/Principal

William D. Huse

Corporate Officer/Principal

Chen-Ming Yu

Corporate Officer/Principal

Kurt Wheeler

Corporate Officer/Principal

Fredric Cohen

Corporate Officer/Principal

Dale M. Edgar

Director/Board Member

Edward S. Dunn

Corporate Officer/Principal

Vincent J. Gurnari

Sales & Marketing

P. Reed Maurer

Corporate Officer/Principal

Leeftijdsdistributie van bedrijfsleiders

Ratio vrouwen/mannen

Man	26
Vrouw	9

Waarvan leden van het uitvoerend comité

Man	7
Vrouw	2

Waarvan bestuurders

Man	9
Vrouw	2

Herzieningen

Herziening omzet 1 jaar

Herziening omzet 4 maanden

Herziening omzet 1 maanden

Herziening WPA 1 jaar

Herziening WPA 4 maanden

ESG MSCI

ESG

Milieu

Sociaal

Bedrijfsvoering

Controverse

ethische controverses

controverses inzake mensenrechten

controverses belastingsubsidies

In overeenstemming met islamitisch financieren

Eli Lilly and Company is wereldwijd een van de belangrijkste farmaceutische concerns. De omzet per therapeutisch vakgebied is als volgt onderverdeeld: - endocrinologie (65,5%): producten voor de behandeling van osteoporose, diabetes en groeiproblemen; - oncologie (19,4%); - immuunziektes (9,8%); - neurologie (3,3%): voornamelijk geneesmiddelen bestemd voor de behandeling van depressie en schizofrenie; - overige (2%). De geografische verdeling van de omzet is als volgt: Verenigde Staten (67,4%), Europa (15,4%), Japan (4%), China (3,7%) en overige (9,5%).

Werknemers

47.000

Sector

Farmaceutische producten

Agenda

07/08 - Q2 2025 Cijferpublicaties

Meer informatie over het bedrijf